STOCK TITAN

CGEN (COMPUGEN LTD) CFO David Silberman discloses initial share and option holdings

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
3

Rhea-AI Filing Summary

COMPUGEN LTD filed an initial ownership report for its Chief Financial Officer, David Silberman. The filing lists his current equity holdings rather than new market transactions.

He directly holds Ordinary Shares and two sets of share options over Ordinary Shares. One option covers 65,000 underlying Ordinary Shares at an exercise price of $1.6900 per share, expiring on July 31, 2034. A second option covers 24,000 underlying Ordinary Shares at an exercise price of $1.4600 per share, expiring on August 5, 2035.

Footnotes explain that these options and related RSUs vest over time starting on September 30, 2026, with the remaining portions vesting in regular quarterly installments, subject to Mr. Silberman’s continued service to the company.

Positive

  • None.

Negative

  • None.
SEC Form 3
FORM 3UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0104
Estimated average burden
hours per response:0.5
1. Name and Address of Reporting Person*
Silberman David

(Last)(First)(Middle)
C/O COMPUGEN LTD.
26 HAROKMIM STREET

(Street)
HOLON5885849

(City)(State)(Zip)

UNITED STATES

(Country)
2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026
3. Issuer Name and Ticker or Trading Symbol
COMPUGEN LTD [ CGEN ]
3a. Foreign Trading Symbol
[CGEN]
5. If Amendment, Date of Original Filed (Month/Day/Year)
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Financial Officer
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares35,500(1)D
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year)3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Share Option (right to buy) (2)07/31/2034Ordinary Shares65,000$1.69D
Share Option (right to buy) (3)08/05/2035Ordinary Shares24,000$1.46D
Explanation of Responses:
1. Represents restricted stock units ("RSUs"). 17,500 RSUs vest 50% on September 30, 2026 and the remainder in 8 equal quarterly installments thereafter; and 18,000 RSUs vest 25% on September 30, 2026 and the remainder vests in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer.
2. This option vests 50% on September 30, 2026 and the remainder vested or vests in 8 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer.
3. This option vests 25% on September 30, 2026 and the remainder vests in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer.
/s/ David Silberman03/18/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does the Form 3 filing for COMPUGEN LTD (CGEN) disclose about David Silberman?

The Form 3 shows Chief Financial Officer David Silberman’s existing equity holdings in COMPUGEN LTD, including Ordinary Shares and share options, providing a baseline view of his ownership as an insider rather than recording new market trades.

How many COMPUGEN LTD share options does CFO David Silberman hold in this Form 3?

The filing lists two option grants: one over 65,000 underlying Ordinary Shares at $1.6900 per share and another over 24,000 underlying Ordinary Shares at $1.4600 per share, both held directly by David Silberman.

What are the vesting terms for David Silberman’s COMPUGEN LTD RSUs in this filing?

Footnotes state that 17,500 RSUs vest 50% on September 30, 2026 and then in eight equal quarterly installments, while 18,000 RSUs vest 25% on that date and the rest in twelve equal quarterly installments, contingent on continued service.

When do David Silberman’s COMPUGEN LTD share options expire according to the Form 3?

One share option series over Ordinary Shares expires on July 31, 2034, and the second expires on August 5, 2035. Both options are held directly and have fixed exercise prices specified in the filing.

Does the COMPUGEN LTD (CGEN) Form 3 show any insider buying or selling by David Silberman?

The Form 3 is an initial ownership report and lists holdings only. Transaction summaries indicate no recorded buys, sells, gifts, or exercises, so it functions as a baseline disclosure rather than evidence of recent trading activity.
Compugen

NASDAQ:CGEN

View CGEN Stock Overview

CGEN Rankings

CGEN Latest News

CGEN Latest SEC Filings

CGEN Stock Data

205.18M
92.66M
Biotechnology
Healthcare
Link
Israel
Holon